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Abstract
Background: The Kennedy pathway generates phosphocoline and phosphoethanolamine through its two branches.
Choline Kinase (ChoK) is the first enzyme of the Kennedy branch of synthesis of phosphocholine, the major component of
the plasma membrane. ChoK family of proteins is composed by ChoKa and ChoKb isoforms, the first one with two different
variants of splicing. Recently ChoKa has been implicated in the carcinogenic process, since it is over-expressed in a variety of
human cancers. However, no evidence for a role of ChoKb in carcinogenesis has been reported.
Methodology/Principal Findings: Here we compare the in vitro and in vivo properties of ChoKa1 and ChoKb in lipid
metabolism, and their potential role in carcinogenesis. Both ChoKa1 and ChoKb showed choline and ethanolamine kinase
activities when assayed in cell extracts, though with different affinity for their substrates. However, they behave differentially
when overexpressed in whole cells. Whereas ChoKb display an ethanolamine kinase role, ChoKa1 present a dual choline/
ethanolamine kinase role, suggesting the involvement of each ChoK isoform in distinct biochemical pathways under in vivo
conditions. In addition, while overexpression of ChoKa1 is oncogenic when overexpressed in HEK293T or MDCK cells, ChoKb
overexpression is not sufficient to induce in vitro cell transformation nor in vivo tumor growth. Furthermore, a significant
upregulation of ChoKa1 mRNA levels in a panel of breast and lung cancer cell lines was found, but no changes in ChoKb
mRNA levels were observed. Finally, MN58b, a previously described potent inhibitor of ChoK with in vivo antitumoral
activity, shows more than 20-fold higher efficiency towards ChoKa1 than ChoKb.
Conclusion/Significance: This study represents the first evidence of the distinct metabolic role of ChoKa and ChoKb
isoforms, suggesting different physiological roles and implications in human carcinogenesis. These findings constitute a
step forward in the design of an antitumoral strategy based on ChoK inhibition.
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Introduction
Human choline kinase alpha (ChoKa) and beta (ChoKb) are
members of the choline kinase family. In mammals this family is
encoded by two separate genes, CHKA and CHKB, resulting in
three different proteins with a choline/ethanolamine kinase
(ChoK/EtnK) domain: ChoKa1 (NP_001268), ChoKa2
(NP_997634) and ChoKb1 (NP_005189) [1]. ChoKa1 differs
from ChoKa2 in only an extra stretch of 18 amino acids, while
ChoKb differs from ChoKa1 and ChoKa2 in approximately
40%. The presence of the ChoK/EtnK domain confers the
capacity to catalyze the phosphorylation of choline (Cho) to
phosphocholine (PCho) [1]. This constitutes the first step in the
biosynthesis pathway of phosphatidylcholine (PC) [2]. PC is the
major phospholipid in eukaryotic membranes and plays a critical
role in membrane structure and also in cell signalling [2]. ChoK
enzymes could be implicated also in the synthesis of phosphati-
dylethanolamine (PE), using as substrate ethanolamine to render
phosphoethanolamine (PEtn) [1,3–5].
Previous studies suggest that ChoK acts as a dimeric protein
[6,7] and the proportion of the different homo- or hetero- dimer
population has been proposed to be tissue-specific [8]. Further-
more, the combination between choline kinase isoforms results in a
different level of ChoK activity in vitro under cell-free systems
conditions. Thus, the a/a homodimer is the most active choline
kinase form, the b/b homodimer the less active, and the a/b
heterodimer has an intermediate phenotype [8].
The specific phospholipase D-driven hydrolysis of PC generates
choline and signal transduction metabolites such as PA (phospha-
tidic acid), and its derivatives LPA (lysophosphatidic acid) and
DAG (diacylglycerol), that are important in mitogenesis and
cellular transformation [9–11]. Choline gets further converted by
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in murine fibroblasts [12]. In addition, several oncogenes such as
RAS or RHOA increase ChoKa activity resulting in higher
intracellular levels of PCho [13–16]. Magnetic resonance
spectroscopy (MRS) studies have revealed abnormal phospholipid
metabolism in cancer cells [17,18]. Furthermore, high levels of
PCho have been found in tumoral cells as well as in tumour
samples of cancer patients compared with the normal counterparts
in breast, prostate, brain and ovarian cancer [19–25]. The
increase in phosphoethanolamine has been also reported in
transformed cells or tumor samples using MRS, although it
contributes to a much lesser extent, compared with the increase of
PCho, to the phosphomonoester peak [26].
The implication of ChoKa in cell growth, proliferation,
initiation and progression of cancer is well documented. ChoKa
is overexpressed in some of the most common cancers, such as
breast, lung, colorectal, prostate [27–30] and bladder (unpublished
observations). Furthermore, it has oncogenic activity when
overexpressed in human cells [15]. Increased ChoKa mRNA
levels have been recently described as an independent prognostic
marker in non small cell lung cancer patients [30]. Also, human
breast cancer cell lines show upregulation of ChoKa but not
ChoKb, when compared with normal mammary epithelial cells
[21]. In that sense, it has been recently reported that in the
prostate tumor mouse model (TRAMP), using IHQ immunode-
tection of ChoKb, a low level expression of ChoKb was found in
tumoral samples compared with wild type tissues [31].
The implication of members of the Rho GTPase family in
cancer onset and progression has been extensively described [32–
35]. Evidence that ChoK is involved in malignant transformation
along with Ras and RhoA has been provided [14,15,36].
Moreover, the activity of ChoKa is modulated by known effectors
of both Ras and RhoA [15,29].
Pharmacological inhibition of ChoKa has been proposed as a
novel antitumoral strategy [2]. A strong support to this strategy is
based on the use of MN58b, a well-characterized ChoKa
inhibitor, which displays a potent antiproliferative effect in several
tumoral cell lines in vitro, and a strong reduction of tumor growth
in nude mice xenografts [14,37–40].
We have compared the biochemical and biological properties of
ChoKa and ChoKb, and demonstrate that besides their
homology, the latter is not able to induce cell transformation in
HEK293T or MDCK cells. Moreover, we suggest differential
behaviour between a and b isoforms in phospholipids metabolism.
Finally, the antitumoral properties of MN58b can be attributed to
its specific inhibition of ChoKa. The implications of these findings
are discussed.
Results
Characterization of enzymatic properties of ChoKa1 and
ChoKb isoforms
The activity of both choline kinase isoforms, ChoKa1 and
ChoKb, has been described previously in different mammalian
tissues, however their choline kinase and/or ethanolamine kinase
activities are not fully characterized [1,4,41–43]. Thus, we first
carried out a comparative analysis of the in vitro kinase activity of
the two human ChoKa1 and ChoKb isoforms, regarding their
ability to phosphorylate choline and ethanolamine. HEK293T
cells were transfected with appropriate expression vectors carrying
the human CHKA or CHKB genes or an empty vector, and tested
for ChoK and EtnK activity. Expression levels achieved were
checked by Western Blot (Figure 1a), and the relative enzymatic
activity from cell extracts estimated. Both ChoKa1 and ChoKb
displayed choline and ethanolamine kinase activities under these
experimental conditions, but the rate of conversion was apparently
different (Figure 1b).
We further analyze ChoK and EtnK kinetic activities for
ChoKa1 and ChoKb isoforms using the recombinant enzymes.
DH5a Escherichia coli were transformed with the gene encoding for
human ChoKa1 or ChoKb and an enzymatic in vitro assay for
either ChoK or EtnK activities performed. Michaelis constants
(Km) for each isoform for the different substrates were obtained
(Table 1). ChoKb showed a Km for choline 2.8 times higher than
ChoKa1. By contrast, the Km of ChoKb for ethanolamine was
lower than ChoKa1. These results suggest that in cell-free systems
choline is a better substrate for ChoKa1 (2.85 fold) than ChoKb,
Figure 1. Characterization of choline and ethanolamine kinase
activity of ChoKa1 and Chokb1 in HEK293T cells. HEK293T cells
were transfected with eukaryotic expression vectors of human ChoKa1
and ChoKb1 gene. pCDNA3b empty vector was used as control. A)
Overexpression of ChoKa1 and ChoKb1 in HEK293T cells detected by
Western Blot. GAPDH detection was used as control of expression level.
B, C) In vitro ChoK (B) and EtnK (C) activity of choline kinase a1 and b1
isoforms in cell-free extracts of HEK293T transfected cells. Percentage of
conversion of
14C-choline or
14C-ethanolamine to the phosphorylated
product is represented. The experiment was performed in duplicate
samples, repeated 4 times, and mean6SEM values from all experiments
estimated.
doi:10.1371/journal.pone.0007819.g001
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than ChoKa1.
ChoK isoforms are differentially regulated by Ras and Rho
GTPases
Since Ras and RhoA GTPases are upstream regulators of
ChoKa1 [15,28], some of the most studied proteins of the small
GTPase family including H-Ras, and the Rho-family members
RhoA and Cdc42 were tested as potential upstream modulators of
ChoKb. To that end, an in vitro ChoK and EtnK activity assay was
performed in HEK293T cells transfected with the constitutive
active mutants of each GTPase (Fig. 2a) and either ChoKa1 and
ChoKb. As shown in Figure 2, none of the GTPases tested were
able to significantly increase choline or ethanolamine kinase
activity of ChoKb. By contrast, under similar conditions, Ras and
RhoA were able to induce a statistically significant change in the
activation of both ChoK and EtnK activities of ChoKa1 (Fig. 2b
and 2c).
Differential role between ChoK isoforms in cell
transformation and tumorigenesis
The implication of ChoKa1 in cell transformation and human
carcinogenesis has been extensively studied, and it has been shown
to display oncogenic activity [15,36]. Due to its extensive
homology, we investigated if ChoKb could induce cellular
transformation when overexpressed in non-tumorigenic cells.
First, the ability of ChoKb-transfected cells to promote anchorage
independent cell growth was determined using the cell line
HEK293T. As previously reported, ChoKa1 induced a significant
increase in the number of soft agar colonies [15]. By contrast,
under similar conditions, ChoKb overexpression had no signifi-
cant effect on the number nor the size of the colonies when
compared to those generated by control, empty vector transfected
HEK293T cells (Fig. 3). These results were confirmed using
another non-tumorigenic cell line from a different species such as
MDCK, obtaining similar results despite of the lower level of
overexpression of both ChoK isoforms compared to the
HEK293T cells. The differential level of expression obtained
was due to the rather different efficiency in transfection for each
cell lines (data not shown).
The ability of ChoKb to induce tumour growth was also
investigated. Both ChoKa1- and ChoKb-transfected HEK293T
or MDCK cells were subcutaneously inoculated into athymic
mice. As shown in Fig. 4, the overexpression of ChoKa1 was
sufficient to induce tumour growth in immunosuppressed mice in
the both cell systems analyzed. By contrast, cells overexpressing
ChoKb were not able to induce tumor growth under similar
conditions. As indicated above, comparison in tumor growth rates
between both cell lines is related to the diverse efficiency of
transfection, much higher in HEK293T (aproxm. 80–90%) than
MDCK (aproxm. 15–20%). These results are in keeping with
those obtained in the soft-agar experiments, and strongly indicate
that overexpression of ChoKb is not sufficient to induce tumor
growth under conditions where ChoKa1 does.
ChoKb isoform shows preferential EtnK activity in vivo
We next investigated if there was any difference in the
enzymatic activity of both ChoK isoforms under in vivo conditions
that could explain their differential biological activity. Thus, the
activity of ChoKa1 and ChoKb as ChoK and/or EtnK in a
whole-cell system was tested. Intracellular lipids of human
HEK293T overexpressing ChoKa1, ChoKb or transfected with
an empty vector, were extracted an analyzed. Both, the insoluble
lipid fraction containing the hydrophobic lipids and total protein
content were used as loading control obtaining similar results. As
shown in Figure 5A, the intracellular phosphoethanolamine levels
were increased to a similar extent in ChoKa12 or ChoKb-
transfected cells. However, the intracellular phosphocholine levels
of ChoKb-transfected cells were not significantly different to that
of control cells, while ChoKa1-transfected cells showed an
increased intracellular PCho levels (Figure 5B). Similar results
were obtained using epithelial cells of different origins: human
breast adenocarcinoma cells SK-Br-3 (Fig. 5C, D) or the human
Non Small Cell Lung Cancer (NSCLC) cell line H1299 (Fig. 5E,
F). In addition, in all cell lines analyzed, protein expression was
also determined by Western Blot analysis (Fig. 5G).
Thus, the differential enzymatic activity of ChoKa1 and
ChoKb found in HEK293T is not cell line specific. These results
indicate that ChoKa1 but not ChoKb, is able to induce increased
intracellular levels of PCho under in vivo conditions. However,
under the same conditions both enzymes are able to generate
phophorylethanolamine. Thus, even though ChoKb displays both
ChoK and EtnK activity under in vitro conditions, it shows
preferential EtnK activity in vivo.
Increased levels of ChoKa mRNA but not ChoKb in
tumor-derived cell lines
In order to further investigate the relevance of each ChoK
isoenzyme in tumorogenesis, we determined the levels of both
ChoKa and ChoKb mRNA in a panel of human tumour-derived
cell lines by quantitative PCR technology. A panel of breast and
lung cancer cell lines were compared with the primary, senescent,
non-tumoral cell line HMEC (Human Mammary Epithelial Cells)
or the immortalized, non-tumorogenic MCF10A cells as control
breast cell lines, and primary Bronchial Epithelial Cells (BEC) as
control lung cell line. All tumoral cell lines tested significantly
overexpress ChoKa mRNA compared with the normal cell lines,
whereas no changes were found for ChoKb mRNA levels (Fig. 6).
These results indicate that ChoKb is not specifically upregulated
in breast or lung cancer cells, suggesting that high levels of ChoKb
are not required for the promotion of cancer.
MN58b is a specific inhibitor of ChoKa isoform
The implication of ChoKa in human carcinogenesis has been
used for the design of specific inhibitors of this enzyme as a novel
anticancer strategy [2,14,37]. MN58b is the leading compound to
support this novel strategy since it has shown a potent antitumoral
activity under in vivo conditions versus human colon, lung, breast
and bladder tumor models [15,37].
Table 1. Michaelis constant (Km) of ChoKa and b isoforms for
choline and ethanolamine.
Substrate Isoform Km
1 SEM FOLD
2
Choline ChoKa 0.20 0.04 1
ChoKb 0.57 0.08 2.85
Ethanolamine ChoKa 12.01 2.14 5.83
ChoKb 2.01 0.42 1
1Data are represented in milliMolar.
2Referenced to the lowest Km.
Km of the different isoforms of ChoK for each substrate is indicated in each
case. The results were obtained from four independent experiments using the
logarithmic Michaelis-Menten formula as described in Material and Methods.
doi:10.1371/journal.pone.0007819.t001
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60% homology with that of ChoKa1 [1]. The higher degree of
homology lies within the choline/ethanolamine kinase domain. This
homology could make it susceptible to a similar inhibition for both
ChoKa1a n dC h o K b with the same inhibitors. Thus, we have
investigated the specificity of MN58b towards these two ChoK
isoenzymes in order to verify if its antitumoral effect is specifically
related to the inhibition of the alpha isoform, that is the one implicated
in tumor progression, or the drug similarly affects both isoforms. Using
the human ChoKa1a n dC h o K brecombinant proteins, we performed
an in vitro ChoK activity inhibition assay using increasing MN58b
concentrations, determining the IC50 for each enzyme. As expected,
despite the high similarity displayed between ChoK isoforms, MN58b
showed a much higher specificity against ChoKa1( I C 50=5mM) than
against ChoKb (IC50=107.5 mM). Thus, MN58b is 21.5 times more
potent against ChoKa1 than ChoKb isoform.
Discussion
The family of human choline/ethanolamine kinases comprises
two genes, CHKA and CHKB that codify for three enzymes,
ChoKa1 (52 kDa), ChoKa2 (50 kDa) and ChoKb1 (45 kDa).
Figure 2. Differential activation of choline kinase a1 and b1 isoforms by Ras and Rho GTPases. Choline kinase isoforms were expressed
alone or in combination with the indicated Ras andRhoGTPases andthe in vitro ChoK activity determined. A) Analysisof ectopic expression by Western
Blot in HEK293T transfected cell extracts of ChoKa1 (52 KDa), ChoKb1(45 KDa), RhoA-QL(22 KDa), Cdc42-QL(25 KDa) and H-rasV12 (23 KDa). Empty
vectorswereusedas controls forthe endogenous levels,andGAPDH asloading control. B)andC)In vitrocholinekinaseactivityof ChoKa1 orChoKb1i n
the presence of enhanced expression of constitutive active forms of RhoA, Cdc42 or H-Ras. D) and E) In vitro ethanolamine kinase activity of ChoKa or
ChoKb in the presence of each indicated constitutive active form of GTPase. The results are represented as fold induction of conversion to the
correspondingphosphorylatedmetabolite determined astotalcpm/mgofwholecellularextract,andnormalizedtotheempty vectortransfectedcells as
control.Datashownrepresentthemeanvalues6SEMof3independentexperiments,eachoneperformedwithduplicatesamples.Statisticalsignificance
(p#0.05) is marked by an asterisk comparing to the activity achieved when ChoKa1 or ChoKb1, where appropriate, are transfected alone.
doi:10.1371/journal.pone.0007819.g002
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18 extra amino acids in ChoKa1, as they result from differential
splicing from the same gene, CHKA. While the implication of
ChoKa1 in the regulation of cell growth and cancer has been
extensively demonstrated [13,15,27,28,37,38,44], preliminary
evidence suggest that ChoKb may not be involved in carcinogen-
esis since it is not overexpressed in breast cancer cell lines [21] nor
in the TRAMP mouse prostate cancer model [31].
A distinct human gene family has been described that codifies
for EtnK activity [45], suggesting that EtnK1 is the main enzyme
involved in PE homeostasis. The ChoK/EtnK domain confers to
ChoKa and ChoKb the ability to function as both ChoK and
Figure 3. Anchorage independent cell growth of ChoKa1- and b1-overexpressing cells. A) and B) In vitro ChoK activity of cell-free
extracts from transfected cells at the moment of plating, determined as conversion of
14C-labeled choline to PCho. C) Photographs of a
representative experiment of the soft agar assay. A total of 10
5 cells were plated per 60-mm dish, and the number of colonies quantified after 5-
8 weeks of incubation. D) and E) Computer based automatic quantification of the number of colonies, mean values6SEM is represented. The
assay was performed 3 independent times with triplicate samples obtaining similar results. Statistical significance (p#0.05) is marked by an
asterisk.
doi:10.1371/journal.pone.0007819.g003
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if these previously characterized enzymes showed any selectivity to
each branch of the Kennedy pathway in the denovo synthesis of PCor
PE. It has been recently described the different specificity towards
Cho and Etn of the two isoforms of Cho/EtnK of Tripanosoma brucei.
Whereas TbCho/Etn1 displays only EtnK activity, TbCho/Etn2
displays both ChoK and EtnK activities in vitro [46]. These results are
in keeping with those described for murine EtnK1 that is Etn specific
and EtnK2 that displays a dual ChoK/EtnK function [45,47]. On
the other hand, whereas murine Pcyt1a and Pcyt1b are involved in
PC biosynthesis, Pcyt2 is focused to PE only [48].
However, it is not yet fully understood which ChoK isoform, if
any, contributes in vivo in each pathway to maintain the normal
homeostasis of both PC and PE in biological membranes. The
results shown here confirm that both enzymes have the ability to
phosphorylate choline and ethanolamine under cell-free condi-
tions, either as recombinant proteins produced in E. coli, or in cell
extracts from mammalian cells. However, we found that under
whole cell conditions ChoKa1 has the ability to function as both
ChoK and EtnK, but ChoKb only affects the production of PEtn.
These findings of different roles for a and b isoforms are in
keeping with the information from the recently generated Knock
Figure 4. Overexpression of ChoKb1 is not sufficient to induce tumor growth in athymic nude mice. Xenografts were established by s.c.
injection of transfected HEK293T or MDCK cells in athymic nu/nu nude mice. A) and B) Western Blot analysis of ectopic expression of choline kinase
isoforms in transfected HEK293T or MDCK cells, respectively, before mice inoculation. C) and D) Analysis of choline kinase activity in ChoKa1o rb1
transfected HEK293T or MDCK cells-free extracts before mice inoculation. E) and F) Volume of tumors generated by subcutaneous injection of 10
6
transfected cells. Tumoral volume was calculated according to the formula: Vol=[D * d
2]/2, where D and d are major and minor tumor diameters
respectively. The data from HEK293T represents mean values6SEM from two independent experiments (n1=12; n2=16), the MDCK experiment
correspond to an equivalent experiment with n=12.
doi:10.1371/journal.pone.0007819.g004
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ChoKb KO mice (rmd mice) are viable, but develop a rostrocaudal
muscular dystrophy, while normal PC lipid levels are found in
most tissues analyzed except in hindlimb skeletal muscle [49].
Therefore, ChoKa is sufficient to maintain normal PC levels in
most tissues. By contrast, the lack of ChoKa results in embryonic
lethality, and ChoKa
+/2 heterozygous mice display an accumu-
lation of Cho and a reduction in PCho in liver and testis,
suggesting that there is no ChoKb compensation for PC
biosynthesis in vivo. These results suggest different roles in vivo for
both ChoKa and ChoKb isoforms. Furthermore, the attenuated
levels in PE found in ChoKa
+/2 heterozygous mice suggest the
involvement of ChoKa not only in the biosynthesis of PC but also
in the PE pathway. This is also consistent with the fact that in
ChoKb KO mice, PE levels are unaffected, indicating that PE
homeostasis is fully maintained with the EtnK1 and ChoKa
proteins intact.
The group of Ishidate has provided valuable information about
the in vitro activity of ChoK from different mouse tissues, and they
have postulated that the most active form for choline kinase
activity is the a/a homodimer followed by a/b heterodimers,
being the b/b homodimer the least active form [8]. The in vivo
Figure 5. Intracellular phosphocholine and phospoethanolamine levels after ChoKa1 or ChoKb1 transfection in human cells.
HEK293T, SK-Br-3 or H1299 cells were transfected with eukaryotic expression vectors of human ChoKa1 and ChoKb1 gene or pCDNA3b empty vector
used as control. A), C) and E) Intracellular EtnK activity of choline kinase a1 and b1 isoforms in whole cells in HEK293T, H1299 and SK-Br-3 cells
respectively. B), D) and F) Intracellular ChoK activity of ChoKa and ChoKb isoforms in whole cells in HEK293T, H1299 and SK-Br-3 cells respectively.
The amount of
14C-PCho and
14C-PEtn were extracted and quantified as described in Materials and Methods. The experiment was performed in
triplicate samples, repeated 3 times, and mean values6SEM from all experiments estimated. Statistical significance (p#0.05) is marked by an asterisk.
A typical radio-labelling experiment results in about 70% of radioactive compound incorporation into the cells. G) Representative Western Blot of
ectopic ChoKa1 or ChoKb1 expression in each cell line. Baseline values chosen as 1-fold in the graphs for each cell line represent: HEK293T cells
(PCho: 1153 cpm; PEtn: 1231 cpm); H1299 cells (PCho: 22821 cpm; PEtn: 13339 cpm), and SK-Br-3 cells (PCho: 18620 cpm, PEtn: 3151 cpm).
doi:10.1371/journal.pone.0007819.g005
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The in vivo activity of ChoKb is focused in PE biosynthesis and
displays higher Km for choline than ChoKa, this could be the
reason why b/b dimers show low ChoK activity. When ChoKb
was overexpressed we observed an increase in the intracellular
levels of PEtn but not of PCho. However no differences were
found between both isoforms for the generation of PEtn, since
both display similar EtnK activity.
PCho has been proposed to promote mitogenesis in mammalian
cells [12]. In keeping with this, magnetic resonance spectroscopy
techniques have revealed higher levels of phosphomonoesthers in
tumoral samples when compared to their normal counterparts
[19–24]. Moreover, overexpression of ChoKa1 is oncogenic [15],
and enhanced ChoKa activity is a frequent feature in tumoral
samples compared to normal tissues [27,28]. Taken together all
these results strongly indicate that ChoKa1 activity and PCho
levels have a strong implication in cancer. Furthermore,
overexpression of ChoKa1 results in an increase in EtnK activity
and PEtn levels. However the latter effect by itself is not sufficient
to induce cell transformation, since overexpression of ChoKb does
not induce enhanced colony formation in soft-agar or tumor
growth in nude mice. These results are consistent with the
hypothesis that it is the production of PCho what is linked to cell
proliferation and transformation mediated by ChoK, and that the
production of PEtn may not be sufficient or relevant in this
process.
The above results suggest that the two ChoK isoforms
investigated, besides their similarity in their primary sequences,
are implicated in different metabolic pathways. Thus while
ChoKa1 impinges into both PC and PE synthesis, ChoKb affects
only PE synthesis. Furthermore, the transformation capacity seems
to be exclusive to the ChoKa isoform. However, since in the
human HEK293T, Sk-Br-3 and H1299 cell lines, ChoKa1
overexpression produces elevated levels of both PCho and PEtn,
while similar ChoKb overexpression results only in higher levels of
PEtn but normal levels of PCho, we can not rule out the possibility
that cell transformation requires both ChoK and EtnK activities.
Consistent with the idea that links oncogenic activity to the
function of ChoKa, but not ChoKb, the antiproliferative and
antitumoral activity of MN58b was only associated to the activity
of ChoKa. Furthermore, as previously reported, the in vivo
treatment with MN58b results in a specific decrease of PCho
levels in the tumours but no significant effect on the levels of PEtn
[51]. Previous results from our group have demonstrated that
MN58b also inhibits choline transport [38]. However this effect
has a little influence in the antiproliferative and antitumoral
activity of the drug since HC-3, a much more potent inhibitor of
choline transporters, is far less potent as an antiproliferative agent
than MN58b [2]. Furthermore, MN58b has a differential effect on
either normal or tumor cells, a strong demonstration of a
differential activity due to ChoK inhibition [38–40]. These results
are also in keeping with the observation that ChoKa but not
ChoKb is a downstream target of oncogenic molecules such as Ras
and RhoA. Thus, while Ras activates ChoKa through Ral-GDS
and PI3K [29], and RhoA activates ChoKa through ROCK [15],
none of these oncogenic GTPases affect ChoKb activity under
similar conditions. Again, these results indicate that although both
ChoK enzymes are able to phosphorylate both choline and
ethanolamine under cell-free systems conditions, they display
different affinities for these substrates, and in whole-cell assays
conditions they are governed by distinct regulatory pathways.
Finally, the involvement of ChoKb in breast and lung cancer
has been studied, ChoKa and b mRNA levels were determined by
Q-PCR. All tumour-derived cell lines assayed significantly
overexpress ChoKa mRNA, while no changes were found in the
expression of ChoKb. Similar results have been recently reported,
Figure 6. Comparative expression of ChoKa1 and ChoKb1 mRNA in a panel of cancer cell lines. Q-PCR was performed to determine the
level of expression of mRNA in non-tumorogenic mammary cell lines (HMEC, MCF10A), breast cancer cell lines (MDA-MB435, MDA-MB468, T47D,
MCF7), non-tumorogenic lung cells (BEC) and lung cancer cell lines (H510, H82). The data were normalized with the endogenous 18S ribosomal RNA.
For the comparison between tumoral and non-tumoral cell lines, the 2
2DDCt method was applied and log10 RQ is represented. Note that the data are
referred to the Human Mammary Epithelial Cells (HMEC) mRNA levels in breast cell lines and no significant difference in the level of both ChoK
isoforms mRNA was found with the normal MCF10A cell line. The reference for lung cancer cells was the primary Bronchial Epithelial Cells (BEC).
doi:10.1371/journal.pone.0007819.g006
ChoKa and b in Carcinogenesis
PLoS ONE | www.plosone.org 8 November 2009 | Volume 4 | Issue 11 | e7819using semi-quantitative PCR in breast cancer cell lines [21]. In
addition, it has been recently described that elevated mRNA levels
of ChoKa is a poor prognostic factor in lung cancer [30]. These
results suggest that ChoKa but not ChoKb is playing a crucial role
in human carcinogenesis.
The results shown here suggest that ChoKb and its produced
metabolites are not implicated in human cell transformation.
Therefore, all the efforts aimed at dilucidating the involvement of
ChoK activity in the diagnosis, prognosis and treatment of cancer
have to be focused in the ChoKa isoform. In keeping with this,
recently the use of specific monoclonal anti-ChoKa antibodies has
been proposed as a diagnostic tool in human cancer [52].
Furthermore, the newly designed antitumoral agents are expected
to be more specific and hence less toxic than the actual drugs used
in conventional chemotherapy. Due to the high structural
homology displayed by both choline kinase proteins, the search
for new anticancer agents based on their ability to interfere with
ChoK activity, must exhibit stronger antiproliferative activity
based on their specificity towards the ChoKa isoform.
The lack of specific inhibition of ChoKb by these newly
designed compounds represents a new feature to take into account
for the chemical improvement of ChoKa inhibitors with potential
antitumoral activity. Furthermore, non-specific drugs affecting
ChoKb may result in a muscular disease produced by the lack of
cell membrane lipid reparation in muscle tissue.
In addition, it has been recently demonstrated using a genetic
approach that the specific inhibition of ChoKa by shRNA displays
antiproliferative and antitumoral activity The high specificity of
this technology provides definitive evidence of an antitumoral
strategy based on ChoKa inhibition, supporting previous results
with the pharmacological inhibitors. [53–55]
Thus, despite the high homology and similar activity displayed
under cell-free conditions, ChoKa1 and ChoKb isoforms show a
different substrate ability and behave very differently under in vivo
conditions, suggesting that in human cells, ChoKb behaves as an
EtnK and its overexpression is not able to induce higher
intracellular levels of PCho. As a consequence, ChoKb has no
effect on cell proliferation and does not contribute to oncogenic
transformation. Finally, ChoKa but not ChoKb, should be used as
the molecular target for the design of anticancer drugs aiming at
interfering with choline kinase acitivity.
Materials and Methods
Ethics statement
All animals were handled in strict accordance with good animal
practice as defined by the Guidelines of the Spanish Government
(RD 223/1988, March 14
th and RD 1201/2005 October 10
th).
The animal work has been conducted under the permission and
supervision of the Consejo Superior de Investigaciones Cientificas (CSIC)
Ethic Committee as approved in the context of the appropriate
Research Project.
Cell cultures and transfections
Cells were maintained under standard culture conditions of
humidity (95%), temperature (37uC) and CO2 (5%). Human
Embryonic Kidney (HEK293T), human breast adenocarcinoma
(SK-Br-3) and Canine Kidney Madin-Darby (MDCK) cells were
maintained in DMEM supplemented with 10% FBS, human non-
small cell lung cancer cells H1299 were maintained in RPMI with
10% FBS. HEK293T transfections were performed using calcium
phosphate as previously described [56]. MDCK, SK-Br-3 and
H1299 cells were transfected using lipofectamine reagent (Invitrogen,
CA) following manufacturers recommendations. Eukaryotic expres-
sion vectors encoding for human ChoKa1a n db1i s o f o r m sw e r e
pCDNA3b (Invitrogen, CA) and pLPneo (BD Biosciences Clontech,
CA) respectively, both empty vectors were used as controls but only
pCDNA3b is usually represented (data not shown). Constitutively
activated expression pCDNA3b derivative vectors encoding for
RhoA (QL), Rac1 (QL) and Cdc42 (QL) have been previously
described [57]. Expression vector encoding to the constitutive active
form of H-Ras (V12) have been previously described [29].
Choline kinase in vitro activity assays
Eukaryotic cell extracts activity assays were carried out as
previously described [14]. Cell extracts were incubated for 30 min
at 37uC in a buffer containing 100 mM Tris pH 8, 10 mM MgCl2
and 10 mM ATP and 200 mM (55 mCi/nmol, 2 mCi/ml) of
[methyl-
14C] choline chloride (Amersham Biosciences, UK) for
ChoK assay or 2-[
14C]-ethan-1-ol-2-amine hydrochloride for
EtnK assay (Amersham Biosciences).
For Michaelis-Menten kinetics assay, extracts of E. coli
expressing human ChoKa1 or ChoKb1 were used. A time course
reaction was performed for each substrate, the reaction was
stopped each 2 minutes and a logarithmic scale was represented to
obtain the Km. Specific ChoK inhibitor MN58b was kindly
provided by TCD Pharma SL (Madrid, Spain).
Analysis of phosphocholine and phosphoethanolamine
production in whole cells
HEK293T, SK-Br-3 and H1299 cells were transfected as
described above. After transfection, cells were labelled to
equilibrium adding 1 mCi/ml [methyl-
14C] choline chloride or
1 mCi/ml 2-[
14C]-ethan-1-ol-2-amine hydrochloride to the culture
media for 24 h. Samples were resolved and quantified as
previously described [37]. Briefly, cells were rinsed with PBS
and fixed with 16% ice-cold trichloroacetic acid (TCA). TCA-
soluble material containing choline and phosphocholine was
washed three times with four volumes of diethyleter, dryed under
vacuum and resuspended in water. Samples were resolved by Thin
Layer Chromatography (TLC) on 60A ˚ Silica gel plates (Whatman,
NJ), using as liquid phase 0,9% NaCl: methanol: ammonium
hydroxide (50:70:5; v/v/v). Radioactivity was automatically
quantified by an electronic radiography system (Instantimager,
CT). TCA insoluble material containing hydrophobic lipids was
used as a loading control. The insoluble fraction was dissolved in
0,25N sodium hydroxide and total lipids were analyzed by
scintillation counting.
Anti-choline kinase b1 serum
Human ChoKb1 gene was cloned into a prokaryotic expression
vector (pGEX-4T3) (GE healthcare, UK) and expressed in DH5a
Escherichia coli. Recombinant ChoKb1 was then purified by the
GST system (Amersham Bioscience) following manufacturer’s
recommendations. Purified ChoKb1 was mixed (1:1; v/v) with
Freund’s complete Adjuvant (Sigma-Aldrich, MO) and then
injected i.m. into white rabbits (80 mg/rabbit). Booster injections
were given every 2 weeks (60 mg/rabbit) and the sample
resuspended with Freund’s incomplete Adjuvant (Sigma-Aldrich)
(1:1; v/v).
Analysis of protein expression by Western blot
Equal amounts of cell lysates were resolved by electrophoresis in
a 10% SDS-PAGE. ChoKa expression levels were detected using
monoclonal antibody AD3 as previously described [52]. ChoKb1
was detected using the polyclonal antiserum described above as
primary antibody at a standard dilution of 1/5000. GTPases
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(Upstate, NY), pan-Ras (Santa Cruz Biotechnology), Cdc42 (BD
Biosciences, transduction labs) and GAPDH antibody (Chemicon
International, CA) were used following manufacturers recommen-
dations. HRP-conjugated secondary antibodies were from Santa
Cruz Biotechnology. The specific binding was detected using the
chemioluminiscence detection kit ECL (Amersham Bioscience)
following the manufacturer indications.
Soft agar anchorage-independent growth and in vivo
tumorigenic assays
Anchorage-independent growth assays were performed at 5–6
weeks of incubation in HEK293T and 6–10 weeks in MDCK, as
previously described [15], plating 10
5 cells per 60-mm dish.
Crystal violet staining was performed to enhance colony contrast.
The number of colonies was automatically quantified by computer
based image software (Image J). For the in vivo assays, cells were
injected (10
6 cells per mouse flank) s.c. in nu/nu athymic mice.
Mice were kept under standard laboratory conditions according to
the guidelines of Spanish Government.
Quantitative PCR
ChoKa1o rb1 mRNA levels were quantified by real-time
reverse transcriptase PCR. The RNA was extracted from the cell
lines using QIAshredder following the RNeasy Mini kit (Qiagen,
Inc.) according to the manufacturer’s instructions. The amount of
0.9 mg of total RNA, in a final concentration of 10 ng/ml per
reaction, was retro transcribed by High-Capacity cDNA Archive
Kit (Applied Biosystems) to the cDNA preparation. The reverse
transcription conditions were 25uC for 10 min and 37uC for 2 h.
Then, each cDNA sample was analyzed in triplicate using the ABI
PRISM 7700 Sequence Detector (PE Applied Biosystems). Real-
time PCR was carried out using Taqman Universal PCR Master
Mix (Applied Biosystems), containing ROX to normalize emis-
sions. Primers used for amplification of ChoKa, ChoKb and 18S
ribosomal RNA were purchased from Applied Biosystems as
Taqman Gene Expression Assays (ChoKa1 ID: Hs00608045_m1,
ChoKb1 ID: Hs01925200_s1 and 18S ribosomal RNA ID:
Hs99999901_s1). For thermal cycling, the following conditions
were applied: 10 min at 95uC and 40 cycles of 15 sec at 95uC and
1 min at 60uC. The data are presented as Log10 RQ (Relative
Quantity).
Statistical analysis
Mean comparisons of ChoK activity or in-cell PCho increase
between different groups were performed. Continuous variables
with normal distribution were compared by T-test and non-
normal distribution variables were compared by means of the
Kruskal Wallis and Mann-Whitney U tests. Statistical significance
was defined as p#0.05. The statistical analyses were performed
using SPSS software, version 13.0 (Inc, Chicago, Illinois). The
method used to analyze data from real-time PCR experiments was
2
2DDCt method [58], comparing the relative gene expression
between normal and tumoral cell lines normalized to 18S
ribosomal RNA as endogenous reference gene.
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